EUVIMEDEUVIMED entdecken
Crossref

Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF V600E with promising antiproliferative properties

Hesham A Abou-Zied, Eman A M Beshr, Hesham A M Gomaa, Yaser A Mostafa, Bahaa G M Youssif, Alaa M Hayallah, Mohamed Abdel-Aziz

Archiv der Pharmazie · 2023-04 · 356 (4)

DOI: 10.1002/ardp.202200464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 16.12.2022. Verfasst von Hesham A Abou-Zied und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt. Hauptthemen laut MEDLINE: Chalcones, Antineoplastic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As dual EGFR and BRAF V600E inhibitors, 2‐(3‐cyano‐4,6‐bis(aryl)‐2‐oxo‐1,2‐dihydropyridine‐1‐yl)‐ N ‐(4‐cinnamoylphenyl) acetamide derivatives 8–20 were developed. Compounds 8, 12 , and 13 showed strong antiproliferative activity when the target compounds were synthesized and tested in vitro against four cancer cell lines. These hybrids have a dual inhibition activity on EGFR and BRAF V600E , according to in vitro studies. The EGFR was inhibited by compounds 8, 12 , and 13 with IC 50 values between 89 and 110 nM, which were equivalent to those of erlotinib (IC 50 = 80 nm). Compound 13 was found to be an effective inhibitor of the proliferation of cancer cells (GI 50 = 0.72 µM) and demonstrated hopeful inhibitory activity of BRAF V600E (IC 50 = 58 nm), which is superior to erlotinib (IC 50 = 65 nm). Compound 13 caused apoptosis and showed cell cycle arrest in the G0/G1phase in a study on the MCF‐7 cell line. The new compounds can fit tightly into the active sites of EGFR and BRAF V600E kinases, according to molecular docking analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChalconesAntineoplastic AgentsHumansStructure-Activity RelationshipErlotinib HydrochlorideCell Line, TumorMolecular Docking SimulationProto-Oncogene Proteins B-rafCell ProliferationErbB ReceptorsProtein Kinase InhibitorsDrug Screening Assays, AntitumorMolecular Structure

Stichwörter der Autor:innen

antiproliferativeapoptosisdockinghybridizationkinases

Substanzen

Erlotinib HydrochlorideProto-Oncogene Proteins B-rafChalconesErbB ReceptorsProtein Kinase InhibitorsAntineoplastic AgentsBRAF protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Medicinal Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia, Egypt.
  • Pharmacology Department, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Sphinx University, Assiut, Egypt.

Zitieren

APA

Abou-Zied, H. A., Beshr, E. A. M., Gomaa, H. A. M., Mostafa, Y. A., Youssif, B. G. M., Hayallah, A. M., & Abdel-Aziz, M. (2023). Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF V600E with promising antiproliferative properties. Archiv der Pharmazie, 356(4). https://doi.org/10.1002/ardp.202200464

Vancouver

Abou-Zied HA, Beshr EAM, Gomaa HAM, Mostafa YA, Youssif BGM, Hayallah AM, et al. Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF V600E with promising antiproliferative properties. Archiv der Pharmazie. 2023;356(4). doi:10.1002/ardp.202200464

BibTeX
@article{AbouZied2023,
  author = {Abou-Zied, Hesham A and Beshr, Eman A M and Gomaa, Hesham A M and Mostafa, Yaser A and Youssif, Bahaa G M and Hayallah, Alaa M and Abdel-Aziz, Mohamed},
  title = {Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF V600E with promising antiproliferative properties},
  journal = {Archiv der Pharmazie},
  year = {2023},
  volume = {356},
  number = {4},
  doi = {10.1002/ardp.202200464}
}
Kostenlos starten →